In a patient with a positive purified protein derivative (PPD) tuberculin skin test due to prior Bacillus Calmette‑Guérin (BCG) vaccination, can latent tuberculosis infection be evaluated using a QuantiFERON‑TB Gold interferon‑gamma release assay (IGRA) blood test?

Yes, QuantiFERON-TB Gold (IGRA) Can and Should Be Used in BCG-Vaccinated Patients with Positive PPD

In patients with a positive PPD due to prior BCG vaccination, QuantiFERON-TB Gold (or other interferon-gamma release assays) is specifically recommended and provides superior specificity for detecting true latent TB infection compared to the tuberculin skin test alone. 1

Why IGRAs Are Superior in BCG-Vaccinated Populations

The key advantage stems from the antigens used in the test. QuantiFERON-TB Gold uses synthetic peptides representing two highly specific M. tuberculosis proteins (ESAT-6 and CFP-10) that are:

• Present in all M. tuberculosis strains
• Absent from all BCG vaccine strains 1
• Absent from most nontuberculous mycobacteria (except M. kansasii, M. szulgai, and M. marinum) 1

This specificity means IGRA results are not affected by prior BCG vaccination, unlike the TST which uses purified protein derivative (PPD)—a polyvalent antigenic mixture that cross-reacts with BCG antigens 1, 2.

CDC Guidelines Support This Approach

The CDC explicitly recommends that QuantiFERON-TB Gold may be used in all circumstances where TST is currently used, including:

• Contact investigations
• Evaluation of recent immigrants
• Sequential-testing surveillance programs 1

The 2010 updated CDC guidelines reinforce that IGRAs using M. tuberculosis-specific antigens offer improved specificity over TST, particularly in BCG-vaccinated populations 2.

Clinical Evidence Supporting IGRA Use

Research consistently demonstrates the superiority of IGRAs in BCG-vaccinated populations:

• Specificity improvement: In BCG-vaccinated individuals, IGRAs show dramatically lower false-positive rates. Studies show only 10-21% IGRA positivity in low-risk BCG-vaccinated populations versus 62-85% TST positivity 3, 4, 5

• Concordance issues with TST: The level of concordance between TST and earlier IGRA versions was adversely affected by prior BCG vaccination 6. This discordance actually supports using IGRAs, as it reflects the elimination of BCG-related false positives

• Duration of BCG effect: BCG vaccination can influence TST results for up to 55 years after vaccination 7, making TST unreliable throughout a patient's lifetime if they received BCG

Practical Algorithm for BCG-Vaccinated Patients

For a patient with positive PPD and history of BCG vaccination:

1. Order QuantiFERON-TB Gold (or T-SPOT.TB where available) 1

2. Interpret IGRA results:

   • Positive IGRA = True latent TB infection; proceed with clinical evaluation (chest X-ray) and consider treatment 1, 2
   • Negative IGRA = Likely false-positive TST from BCG; no treatment needed in most cases 3, 4
   • Indeterminate IGRA = Requires clinical judgment and possible repeat testing 2

3. Risk stratification matters: Higher TST induration (≥20mm) and higher-risk exposures increase likelihood of true infection even with BCG history 3, 8

Important Caveats

• IGRA sensitivity concerns: In immunocompromised patients (HIV, organ transplant, immunosuppressive therapy), IGRA sensitivity may be reduced, though it still outperforms TST in specificity 9, 2, 10

• Technical requirements: Blood must be processed within 12 hours of collection 6

• Cost-effectiveness: Using IGRA in BCG-vaccinated populations is cost-saving due to reduced false-positive diagnoses and unnecessary treatment 10

• Sequential testing: Some protocols use TST first, then confirm positive results with IGRA in BCG-vaccinated populations, which is cost-effective 8, 10

The bottom line: A positive PPD in a BCG-vaccinated patient should prompt IGRA testing rather than automatic treatment, as this prevents unnecessary therapy in the majority of cases where the TST represents BCG cross-reactivity rather than true TB infection.